Selected article for: "antigen reduction and immune response"
Author: Steinbuck, Martin P.; Seenappa, Lochana M.; Jakubowski, Aniela; McNeil, Lisa K.; Haqq, Christopher M.; DeMuth, Peter C.
Title: A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
  • Cord-id: y658iat1
  • Document date: 2020_8_18
    • ID: y658iat1
    Snippet: The SARS-CoV-2 pandemic has led to public health, economic, and social consequences that mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) in mice. AMP immunogens are efficiently delivered to lymph nodes, where innate and adaptive immune responses
    Document: The SARS-CoV-2 pandemic has led to public health, economic, and social consequences that mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) in mice. AMP immunogens are efficiently delivered to lymph nodes, where innate and adaptive immune responses are generated. Compared to alum, AMP immunization induced >25-fold higher antigen-specific T cells which produced multiple Th1 cytokines and trafficked into lung parenchyma and respiratory secretions. Antibody responses favored Th1 isotypes (IgG2bc, IgG3) and potently neutralized Spike-2-ACE2 receptor binding, with titers 265-fold higher than the natural immune response from convalescent COVID-19 patients; responses were maintained despite 10-fold dose-reduction in Spike antigen. Both cellular and humoral immune responses were preserved in aged mice. These advantages merit clinical translation to SARS-CoV-2 and other protein subunit vaccines.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and adjuvant cpg: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and adjuvant cpg dna: 1, 2
    • acute respiratory syndrome and adjuvant cpg dna vaccine: 1
    • acute respiratory syndrome and adjuvant dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and adjuvant effect: 1, 2, 3, 4, 5
    • acute respiratory syndrome and adjuvant effective vaccine: 1, 2
    • acute respiratory syndrome and adjuvant target: 1, 2
    • acute respiratory syndrome and adjuvant vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute severe pneumonia and ade antibody dependent enhancement: 1, 2
    • acute severe pneumonia and adjuvant vaccine: 1
    • ade antibody dependent enhancement and adjuvant effect: 1